Zoetis Inc. $ZTS Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 44.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 100,377 shares of the company’s stock after selling 80,976 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Zoetis were worth $7,213,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Prosperity Bancshares Inc purchased a new stake in Zoetis during the fourth quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC purchased a new position in Zoetis in the first quarter valued at approximately $28,000. Root Financial Partners LLC increased its stake in Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in Zoetis during the fourth quarter worth approximately $32,000. Finally, Wellington Grp LLC raised its holdings in Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $73.64 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a twelve month low of $71.45 and a twelve month high of $160.48. The stock has a 50 day moving average of $76.30 and a two-hundred day moving average of $99.01. The stock has a market cap of $30.43 billion, a P/E ratio of 12.13, a P/E/G ratio of 1.31 and a beta of 0.74.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. Zoetis’s dividend payout ratio is currently 34.93%.

Analyst Ratings Changes

ZTS has been the subject of several research analyst reports. BNP Paribas Exane lowered their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday. Morgan Stanley set a $85.00 price target on shares of Zoetis in a research note on Friday, August 7th. JPMorgan Chase & Co. cut their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. William Blair reissued a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Finally, Barclays decreased their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Zoetis presently has a consensus rating of “Hold” and an average price target of $109.62.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.